Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chandra Bhagat PharmaBOM:542934 +4.96%65 Return-on-Tangible-Equity is 16.35% as of Mar. 2026, which is 273% above its 10-year median of 4.38. GuruFocus rates BOM:542934 with a GF Score™ of 65/100 and a GF Value™ of ₹70.16 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 111 Medical Distribution companies, Chandra Bhagat Pharma ranks better than 55.86% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Chandra Bhagat Pharma's annualized net income for the quarter that ended in Mar. 2026 was ₹52 Mil. Chandra Bhagat Pharma's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹318 Mil. Therefore, Chandra Bhagat Pharma's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 16.35%.
The historical rank and industry rank for Chandra Bhagat Pharma's Return-on-Tangible-Equity or its related term are showing as below:
BOM:542934'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0.74 Med: 4.38 Max: 13.04
Current: 9.77
During the past 10 years, Chandra Bhagat Pharma's highest Return-on-Tangible-Equity was 13.04%. The lowest was 0.74%. And the median was 4.38%.
BOM:542934's Return-on-Tangible-Equity is ranked better than 55.86% of 111
companies
in the Medical Distribution industry
Industry Median: 8.78
vs BOM:542934: 9.77
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Chandra Bhagat Pharma Return-on-Tangible-Equity Related Terms
Chandra Bhagat Pharma Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Chandra Bhagat Pharma's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:542934 vs MCK, COR, CAH: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, Chandra Bhagat Pharma's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chandra Bhagat Pharma Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Chandra Bhagat Pharma's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Chandra Bhagat Pharma's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 16.35% mean?
Chandra Bhagat Pharma (BOM:542934) has a Return-on-Tangible-Equity of 16.35% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Chandra Bhagat Pharma and its competitors. This is 273% above median its historical median of 4.38. Over the past decade, Chandra Bhagat Pharma's Return-on-Tangible-Equity has ranged from 0.74 to 13.04. According to the industry distribution chart, Chandra Bhagat Pharma ranks #49 out of 111 companies in the Medical Distribution industry, placing it in the top 44.1%.
Is Chandra Bhagat Pharma's Return-on-Tangible-Equity too high?
Chandra Bhagat Pharma's current Return-on-Tangible-Equity of 16.35% is 273% above median its 10-year median of 4.38. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 13.04. The Medical Distribution industry median Return-on-Tangible-Equity is 8.78. Chandra Bhagat Pharma's value of 16.35% is 86.2% above this industry median. Based on the distribution chart, Chandra Bhagat Pharma ranks #49 out of 111 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Chandra Bhagat Pharma has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chandra Bhagat Pharma's Return-on-Tangible-Equity compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Chandra Bhagat Pharma ranks #49 out of 111 companies for Return-on-Tangible-Equity. This puts Chandra Bhagat Pharma in the upper half of its industry. The industry median Return-on-Tangible-Equity is 8.78. Chandra Bhagat Pharma's value of 16.35% is 86.2% above this benchmark. Historically, Chandra Bhagat Pharma's own Return-on-Tangible-Equity has ranged from 0.74 to 13.04 over the past decade. While the company's 10-year median is 4.38 vs. the industry median of 8.78, Chandra Bhagat Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.78, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chandra Bhagat Pharma's current Return-on-Tangible-Equity of 16.35% is 86.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Chandra Bhagat Pharma and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chandra Bhagat Pharma's current Return-on-Tangible-Equity is 16.35%, which is 273% above median its own 10-year median of 4.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chandra Bhagat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Chandra Bhagat Pharma (BOM:542934) is currently considered Possible Value Trap. The stock's GF Value™ is ₹70.16, compared to a current price of ₹39.36 — trading 43.9% below its estimated fair value. The current Return-on-Tangible-Equity is 16.35%, which is 273% above median its 10-year median of 4.38 and 86.2% above the Medical Distribution industry median of 8.78. Chandra Bhagat Pharma's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Chandra Bhagat Pharma (BOM:542934), the current Return-on-Tangible-Equity is 16.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chandra Bhagat Pharma (BOM:542934) Overvalued in 2026?
Based on GuruFocus' analysis, Chandra Bhagat Pharma stock appears to be undervalued.
The current stock price of ₹39.36 is trading 43.9% below its estimated GF Value™ of ₹70.16.
GuruFocus considers Chandra Bhagat Pharma to be Possible Value Trap.
Key valuation signals for BOM:542934:
Return-on-Tangible-Equity: 16.35% (273% above median its 10-year median of 4.38)
GF Value™: ₹70.16 vs. price of ₹39.36 (43.9% below fair value)
Industry Position: 86.2% above the Medical Distribution median (#49 of 111)
No single metric tells the full story. See the BOM:542934 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chandra Bhagat Pharma Ltd is a pharmaceutical company marketing pharmaceutical, critical care, and health care products across the globe. The company deals in many categories of pharmaceutical products like anticancer, cardiovascular, anti-infective, etc. It offers various forms of pharmaceutical products, like oral solids. tablets, capsules, liquid orals, syrup suspension, injections, liquid, powder, etc. Additionally, the company is also engaged in promoting and marketing of Active Pharmaceutical Ingredients (API's) in India.
65GF Score
Get the complete analysis for BOM:542934
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542934 has been successfully added to your 
